MA30692B1 - Composition pharmaceutique contenant le bicalutamide et procede de son utilisation - Google Patents

Composition pharmaceutique contenant le bicalutamide et procede de son utilisation

Info

Publication number
MA30692B1
MA30692B1 MA31598A MA31598A MA30692B1 MA 30692 B1 MA30692 B1 MA 30692B1 MA 31598 A MA31598 A MA 31598A MA 31598 A MA31598 A MA 31598A MA 30692 B1 MA30692 B1 MA 30692B1
Authority
MA
Morocco
Prior art keywords
composition
bicalutamide
pharmaceutical composition
composition containing
mammal
Prior art date
Application number
MA31598A
Other languages
English (en)
Inventor
Amarjit Singh
Sarabjit Singh
Shivanand Puthli
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA30692B1 publication Critical patent/MA30692B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION PROPOSE UN PROCÉDÉ ET UNE COMPOSITION POUR PRODUIRE UN EFFET ANTI-ANDROGÈNE CHEZ UN MAMMIFÈRE. LE PROCÉDÉ COMPORTE L'ADMINISTRATION D'UNE COMPOSITION PHARMACEUTIQUE À LIBÉRATION MODIFIÉE DE BICALUTAMIDE À UN MAMMIFÈRE, AVEC UNE FRÉQUENCE RÉDUITE D'ADMINISTRATION DES DOSES, POUR LE CONFORT AMÉLIORÉ DU PATIENT ET SA BONNE OBSERVATION DU TRAITEMENT. LA COMPOSITION DE L'INVENTION PRÉSENTE EN OUTRE UNE BIODISPONIBILITÉ SUPÉRIEURE ET UN PROFIL PHARMACOCINÉTIQUE AMÉLIORÉ PAR COMPARAISON AVEC UNE COMPOSITION DE BICALUTAMIDE CLASSIQUE.
MA31598A 2006-07-07 2009-01-30 Composition pharmaceutique contenant le bicalutamide et procede de son utilisation MA30692B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1074MU2006 2006-07-07

Publications (1)

Publication Number Publication Date
MA30692B1 true MA30692B1 (fr) 2009-09-01

Family

ID=39492731

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31598A MA30692B1 (fr) 2006-07-07 2009-01-30 Composition pharmaceutique contenant le bicalutamide et procede de son utilisation

Country Status (16)

Country Link
US (1) US20090317464A1 (fr)
EP (1) EP2046321A4 (fr)
JP (1) JP2009542627A (fr)
KR (1) KR20090057214A (fr)
CN (1) CN101478963A (fr)
AR (1) AR061853A1 (fr)
BR (1) BRPI0714053A2 (fr)
CA (1) CA2655541A1 (fr)
CO (1) CO6150137A2 (fr)
EA (1) EA200970097A1 (fr)
MA (1) MA30692B1 (fr)
MX (1) MX2009000268A (fr)
TN (1) TNSN08530A1 (fr)
UA (1) UA92233C2 (fr)
WO (1) WO2008068770A2 (fr)
ZA (1) ZA200900502B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103860487B (zh) * 2012-12-10 2016-07-06 天津市汉康医药生物技术有限公司 一种比卡鲁胺片及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
JP2005060302A (ja) * 2003-08-12 2005-03-10 Sumitomo Chemical Co Ltd Ｎ−メタクリロイル−４−シアノ−３−トリフルオロメチルアニリンの製造方法および安定化方法
US20060269596A1 (en) * 2005-01-12 2006-11-30 Gary Liversidge Controlled release compositions comprising an acylanilide

Also Published As

Publication number Publication date
CN101478963A (zh) 2009-07-08
AR061853A1 (es) 2008-09-24
EP2046321A4 (fr) 2011-08-31
TNSN08530A1 (en) 2010-04-14
JP2009542627A (ja) 2009-12-03
CA2655541A1 (fr) 2008-06-12
CO6150137A2 (es) 2010-04-20
EP2046321A2 (fr) 2009-04-15
WO2008068770A2 (fr) 2008-06-12
WO2008068770A3 (fr) 2008-10-16
US20090317464A1 (en) 2009-12-24
UA92233C2 (ru) 2010-10-11
BRPI0714053A2 (pt) 2012-12-18
ZA200900502B (en) 2010-06-30
MX2009000268A (es) 2009-01-26
EA200970097A1 (ru) 2009-06-30
KR20090057214A (ko) 2009-06-04

Similar Documents

Publication Publication Date Title
Benson et al. A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models
MY199017A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NZ598732A (en) Dosage regimen for administering a cd19xcd3 bispecific antibody
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
TN2012000270A1 (en) Methods and low dose regimens for treating red blood cell disorders
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EP2493507A4 (fr) Antagonistes et variants ax213 et ax132 pcsk9
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
WO2010068810A3 (fr) Amides substitués, et leurs procédés de production et d'utilisation
PH12014500371A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
SG157379A1 (en) Hydroxybenzoate salts of metanicotine compounds
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
WO2008073466A3 (fr) Alpha b-cristalline en tant que traitement de l'inflammation
MA30692B1 (fr) Composition pharmaceutique contenant le bicalutamide et procede de son utilisation
ATE522537T1 (de) (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis